Yassaman Vafai1, Edwina H Yeung1, Rajeshwari Sundaram2, Melissa M Smarr3, Nicole Gerlanc4, William A Grobman5, Daniel Skupski6, Edward K Chien7,8, Stefanie N Hinkle1, Roger B Newman9, Deborah A Wing10,11, Angela C Ranzini8,12, Anthony Sciscione13, Jagteshwar Grewal1, Cuilin Zhang1, Katherine L Grantz1. 1. Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. 2. Biostatistics and Bioinformatics Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. 3. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 4. The Prospective Group, Arlington, VA, USA. 5. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 6. New York Presbyterian Queens, Flushing, NY, USA. 7. Women and Infants Hospital of Rhode Island, Providence, RI, USA. 8. Cleveland Clinic, Case Western Reserve University, Cleveland, OH, USA. 9. Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA. 10. School of Medicine, University of California, Irvine, CA, USA. 11. Fountain Valley Regional Hospital and Medical Center, Fountain Valley, CA, USA. 12. Saint Peter's University Hospital, New Brunswick, NJ, USA. 13. Christiana Care Health System, Wilmington, DE, USA.
Abstract
BACKGROUND: The association between obesity (body mass index (BMI) ≥ 30 kg/m2) and pattern of medication use during pregnancy in the United States is not well-studied. Higher pre-pregnancy BMI may be associated with increases or decreases in medication use across pregnancy as symptoms (e.g. reflux) or comorbidities (e.g. gestational diabetes) requiring treatment that may be associated with higher BMI could also change with advancing gestation. OBJECTIVES: To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status. METHODS: In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clinical sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery. RESULTS: In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19-29.9 kg/m2), more than 70% of pregnant women (77% of women with and 73% of women without obesity) reported taking at least one medication during pregnancy, respectively (adjusted risk ratio (aRR)=1.10, 95% confidence interval (CI)=1.01, 1.20), with 81% reporting two and 69% reporting three or more. A total of 17 classes of medications were identified. Among medication classes consumed by at least 5% of all women, the only class that differed between women with and without obesity was hormones and synthetic substitutes (including steroids, progesterone, diabetes, and thyroid medications) in which women with obesity took more medications (11 vs. 5%, aRR = 1.9, 95% CI = 1.38, 2.61) compared to women without obesity. Within this class, a higher percentage of women with obesity took diabetes medications (2.3 vs. 0.7%) and progesterone (3.4 vs. 1.3%) than their non-obese counterparts. Similar percentages of women with and without obesity reported consuming medications in the remaining medication classes including central nervous system agents (50 and 46%), gastrointestinal drugs (43 and 40%), anti-infective agents (23 and 21%), antihistamines (20 and 17%), autonomic drugs (10 and 9%), and respiratory tract agents (7 and 6%), respectively (p > 0.05 for all adjusted comparisons). There were no differences in medication use by obesity status across gestation. Since the study exclusion criteria limited the non-obese group to women without thyroid disease, in a sensitivity analysis we excluded all women who reported thyroid medication intake and still a higher proportion of women with obesity took the hormones and synthetic substitutes class compared to women without obesity. CONCLUSION: Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.
BACKGROUND: The association between obesity (body mass index (BMI) ≥ 30 kg/m2) and pattern of medication use during pregnancy in the United States is not well-studied. Higher pre-pregnancy BMI may be associated with increases or decreases in medication use across pregnancy as symptoms (e.g. reflux) or comorbidities (e.g. gestational diabetes) requiring treatment that may be associated with higher BMI could also change with advancing gestation. OBJECTIVES: To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status. METHODS: In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clinical sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery. RESULTS: In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19-29.9 kg/m2), more than 70% of pregnant women (77% of women with and 73% of women without obesity) reported taking at least one medication during pregnancy, respectively (adjusted risk ratio (aRR)=1.10, 95% confidence interval (CI)=1.01, 1.20), with 81% reporting two and 69% reporting three or more. A total of 17 classes of medications were identified. Among medication classes consumed by at least 5% of all women, the only class that differed between women with and without obesity was hormones and synthetic substitutes (including steroids, progesterone, diabetes, and thyroid medications) in which women with obesity took more medications (11 vs. 5%, aRR = 1.9, 95% CI = 1.38, 2.61) compared to women without obesity. Within this class, a higher percentage of women with obesity took diabetes medications (2.3 vs. 0.7%) and progesterone (3.4 vs. 1.3%) than their non-obese counterparts. Similar percentages of women with and without obesity reported consuming medications in the remaining medication classes including central nervous system agents (50 and 46%), gastrointestinal drugs (43 and 40%), anti-infective agents (23 and 21%), antihistamines (20 and 17%), autonomic drugs (10 and 9%), and respiratory tract agents (7 and 6%), respectively (p > 0.05 for all adjusted comparisons). There were no differences in medication use by obesity status across gestation. Since the study exclusion criteria limited the non-obese group to women without thyroid disease, in a sensitivity analysis we excluded all women who reported thyroid medication intake and still a higher proportion of women with obesity took the hormones and synthetic substitutes class compared to women without obesity. CONCLUSION: Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.
Authors: Melissa J Azur; Elizabeth A Stuart; Constantine Frangakis; Philip J Leaf Journal: Int J Methods Psychiatr Res Date: 2011-03 Impact factor: 4.035
Authors: Cuilin Zhang; Mary L Hediger; Paul S Albert; Jagteshwar Grewal; Anthony Sciscione; William A Grobman; Deborah A Wing; Roger B Newman; Ronald Wapner; Mary E D'Alton; Daniel Skupski; Michael P Nageotte; Angela C Ranzini; John Owen; Edward K Chien; Sabrina Craigo; Sungduk Kim; Katherine L Grantz; Germaine M Buck Louis Journal: JAMA Pediatr Date: 2018-01-01 Impact factor: 16.193
Authors: Germaine M Buck Louis; Jagteshwar Grewal; Paul S Albert; Anthony Sciscione; Deborah A Wing; William A Grobman; Roger B Newman; Ronald Wapner; Mary E D'Alton; Daniel Skupski; Michael P Nageotte; Angela C Ranzini; John Owen; Edward K Chien; Sabrina Craigo; Mary L Hediger; Sungduk Kim; Cuilin Zhang; Katherine L Grantz Journal: Am J Obstet Gynecol Date: 2015-10 Impact factor: 8.661
Authors: Romy Gaillard; Büşra Durmuş; Albert Hofman; Johan P Mackenbach; Eric A P Steegers; Vincent W V Jaddoe Journal: Obesity (Silver Spring) Date: 2013-05 Impact factor: 5.002